Literature DB >> 18306351

Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals.

Hitoshi Itoh1, Yoko Miyajima, Shinobu Umemura, Robert Y Osamura.   

Abstract

BACKGROUND: Fluorescence in situ hybridization (FISH) is the gold standard for assessing HER-2 status for breast cancers, and paraffin-embedded tissue sections are used routinely for HER-2 FISH. Cytologic samples also are used, but to the authors' knowledge, little is known regarding the reliability of these samples. The objective of this study was to elucidate the usefulness of cytologic specimens for HER-2 FISH testing.
METHODS: Histologic and cytologic specimens from 32 patients with invasive ductal carcinoma of the breast were subjected to comparative analysis of HER-2 status by FISH. FISH was performed by using a PathVysion HER-2 DNA Probe Kit according the manufacturer's instructions. The signal ratios of chromosome enumeration probe 17 (CEP17) and HER-2 were estimated and compared. In 15 cytologic specimens, the distance between signals (HER-2 and CEP17) and the nearest nuclear membrane were measured by using 3-dimensional image analysis and confocal microscopy.
RESULTS: Cytologic and histologic FISH results were compared. Signal ratios of HER-2/CEP17 were lower in cytologic specimens from 26 of 32 patients compared with the histologic material. Three-dimensional image analysis demonstrated that the distance between the CEP17 signal and the nuclear membrane was shorter than the distance between the HER-2 gene and the nuclear membrane.
CONCLUSIONS: The current results demonstrated that CEP17 could be lost more easily through histologic sectioning compared with the cytology results, because CEP17 is closer to the nuclear membrane. FISH analysis in cytologic specimens produced more accurate HER-2/CEP17 ratios, because the whole nucleus was subjected to FISH testing, compared with matched histologic specimens. Copyright (c) American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306351     DOI: 10.1002/cncr.23367

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients.

Authors:  Lin Wang; Xiaobei Wang; Xiu Nie; Ling Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

2.  Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing.

Authors:  Shin-Nosuke Watanabe; Kazuhiro Imai; Hiroshi Nanjo; Yuki Wakamatsu; Yoshihiko Kimura; Yoshihisa Katayose; Shuichi Kamata; Kaori Terata; Eriko Takahashi; Ayano Ibonai; Ayuko Yamaguchi; Hikari Konno; Misako Yatsuyanagi; Chiaki Kudo; Shinogu Takashima; Yoichi Akagami; Ryuta Nakamura; Yusuke Sato; Satoru Motoyama; Kyoko Nomura; Yoshihiro Minamiya
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

3.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.